Ethan Jin

Ethan advises clients on securities and corporate transactions across Greater China, including Hong Kong initial public offerings (IPOs), pre-IPO private equity investments, ongoing compliance and corporate governance matters for Hong Kong-listed companies, follow-on offerings and placings, mergers and acquisitions (M&As), public takeovers, and related regulatory matters. He has represented clients across a wide range of industries and, as lead counsel, has acted for both issuers and underwriters in dozens of Hong Kong IPOs. He also has extensive experience in foreign direct investments into China. 

From 2001 to 2004, Ethan practiced as a PRC-qualified lawyer, providing Chinese legal advice on relevant matters. He is among the few Hong Kong capital markets lawyers with in-depth familiarity with corporate legal practice in both Hong Kong and Mainland China.

Recognized for his strong commercial insight, transaction management capabilities, and ability to navigate complex legal issues, Ethan was named a “Growth Driver” by China Business Law Journal (CBLJ) and included in “The A-List” elite lawyers in China for 2025-2026.

Ethan is a native Mandarin speaker and is fluent in English.

Representative Matters:

Capital Markets

• PATEO in its HK$1.07 billion Hong Kong IPO and global offering 
• Breton Technology in its HK$234 million Hong Kong IPO and global offering 
• Huatai International in Jiuyuan Gene Engineering’s HK$563.9 million Hong Kong IPO and global offering
• Morgan Stanley and CICC in Taimei Technology’s HK$335 million Hong Kong IPO and global offering
• Haitong International in Qunabox Group’s HK$493 million Hong Kong IPO and global offering
• YZY Biopharma in its HK$176 million Hong Kong IPO and global offering
• CICC, Citigroup and Merrill Lynch (Asia Pacific) in Fenbi’s HK$198 million Hong Kong IPO and global offering
• Matrix Partners in the Hong Kong listing of several of its portfolio companies
• Genertec Universal Medical Group Company Limited in its US$150 million convertible bond issue and US$150 million private placement
• HSG (f.k.a. Sequoia China) in its cornerstone investment in multiple Hong Kong IPOs, including Linklogis, JOINN Laboratories, Antengene, etc.
• HSG in the H shares placing of a leading Chinese electric vehicle company
• HSG in the Hong Kong listing of several of its portfolio companies
• A Xiaomi ecosystem company in highly complex pre-IPO consultations with the Hong Kong Stock Exchange (HKEX) regarding unusual customer concentration and listing eligibility issues
• Zhongguancun Science-Tech Leasing in its HK$507 million Hong Kong IPO and global offering
• Haitong International and BOCOM International in China Bright Culture Group’s HK$904 million Hong Kong IPO and global offering
• PW Medtech Group Limited (HKEX: 1358) in the spin-off (PN15) listing of its wholly owned subsidiary Tianxinfu (Beijing) Medical Appliance Co., Ltd.
• CCID Consulting Inc. (HKEX: 2176) in its transition from the Growth Enterprise Market (GEM) to the Main Board of the HKEX
• WuXi Biologics in its US$510 million Hong Kong IPO and global offering
• WuXi AppTec in the pre-IPO restructuring of WuXi Biologics following the delisting of WuXi AppTec from the US stock market
• Rici Healthcare Holdings Limited in its HK$1.07 billion Hong Kong IPO and global offering
• Yoozoo Games in its HK$319 million Hong Kong IPO and global offering
• Tencent in the proposed Hong Kong listing of Douyu
• Wang Tong Yuan in its listing on the Hong Kong GEM
• Universal Medical Financial & Technical Advisory Services Company Limited in its HK$4.2 billion Hong Kong IPO and global offering
• CITIC Asset Management Co., Ltd. in proposed asset injections into Hong Kong-listed companies and reverse takeovers constituting new listings
• China Merchants Securities in Shengjing Bank’s HK$91.35 billion Hong Kong IPO and global offering
• Tonic Industries Holdings Limited in its reverse takeover of HK$6,688 million property assets and business from China Merchants Property
• Development Co., Ltd. and its deemed new listing on the HKEX
• China Pacific Insurance (Group) Co., Ltd. in its US$1.34 billion H shares placing
• UBS and J.P. Morgan in Zhengzhou Coal Mining Machinery Group Co., Ltd.’s HK$22.95 billion Hong Kong IPO and global offering
• Huadian Fuxin Energy Corporation Limited in its HK$2.50 billion Hong Kong IPO and global offering
• Haitong Securities Co., Ltd. in its US$1.67 billion Hong Kong IPO and global offering
• Morgan Stanley in Hilong Holding Limited’s US$129 million Hong Kong IPO and global offering
• J.P. Morgan in China Hongqiao Group Limited’s US$822 million Hong Kong IPO and global offering
• GIC in a block trade involving the secondary sale of shares in a Hong Kong-listed company
• Sateri Holdings Limited in its US$430 million Hong Kong IPO and global offering
• BOCI and UBS in Sinotrans Shipping Limited’s US$1.47 billion Hong Kong IPO and global offering
• China Communications Construction Company Limited in its US$2.4 billion Hong Kong IPO and global offering
• A well-known international USD fund in the Hong Kong De-SPAC transaction of a portfolio technology company
• WZ Group in its proposed Hong Kong IPO and global offering (ongoing)
• A leading Chinese fully integrated coking coal and energy chemicals company in its proposed Hong Kong IPO and global offering (ongoing)
• SG Micro Corp. in its proposed Hong Kong IPO and global offering (ongoing)
• Xiakuo Technology in its proposed Hong Kong IPO and global offering (ongoing)
• InxMed in its proposed Hong Kong IPO and global offering (ongoing)
• Junion Intelligent Technology in its proposed Hong Kong IPO and global offering (ongoing)
• CICC and Guotai Junan International in Xiangdao Chuxing’s proposed Hong Kong IPO and global offering (ongoing)
  

Mergers and Acquisitions

• PW Medtech (HKEX: 1358) as Hong Kong legal counsel in the disposal of its core business to CBPO (NASDAQ: CBPO) in exchange for a 16.66% equity interest in CBPO valued at approximately US$513 million, which constituted a very substantial disposal and a very substantial acquisition for PW Medtech
• Yunfeng Capital in the proposed privatization of a Hong Kong-listed pharmaceutical company
• Centurium Capital in the proposed privatization of a Hong Kong-listed company
• Beijing Gas Blue Sky Holdings Limited in a connected transaction involving an asset acquisition for HK$10 and a whitewash waiver from the Securities and Futures Commission (SFC)
• Beijing Gas Group Company Limited in its subscription for HK$350 million convertible bonds and HK$970 million new shares of Blue Sky Power Holdings Limited, a Hong Kong-listed company
• Yingde Gases and its second largest shareholder in a series of transactions including board restructuring, share placing, defense against a hostile takeover, shareholder dispute, SFC regulatory investigation and US$2.7 billion privatization of Yingde Gases
• LeEco in its acquisition of an 18% stake in Coolpad Group (a Hong Kong-listed company) for HK$2.74 billion
• China Oceanwide Holdings Limited in its proposed acquisition of a Hong Kong-listed company by way of a mandatory general offer and related asset injection
• Joint offerors (Sequoia and the founder) in the HK$1.49 billion privatization of Dongpeng Holdings by way of a scheme of arrangement
• NVC Lighting in matters involving control of the company and shareholder disputes
• Chow Tai Fook in a US$170 million pre-IPO investment in China Huishan Dairy Holdings by way of subscription for exchangeable bonds
• Haitong International Securities Group Limited in a capital issuance to and an offer sale by its controlling shareholder
• China Hi-Tech Group Corporation in its acquisition of Fong’s Industries Company Limited (HKEX: 0641)
• Iron Mining International Limited in a secured convertible loan of US$700 million granted by China Investment Corporation
• Vaillant GmbH in its strategic equity investment in Chigo Holdings Limited
• Air China Limited in its HK$3.227 billion privatization of China National Aviation Company Limited by way of a scheme of arrangement
• Air China Limited in its acquisition of a 12.5% equity interest in Cathay Pacific from CITIC Pacific with a value of US$817 million
• Air China Limited in its strategic acquisition of a 17.5% equity interest in Cathay Pacific, disposal of its interest in Dragonair, and a strategic investment by Cathay Pacific in Air China with an aggregate value of approximately US$2.4 billion
• Nissan in the establishment of a joint venture with Dongfeng Motor
• Chongqing Brewery in the introduction of a strategic investment from Newcastle
• Multiple clients including BMW, 3M, and Siemens in their investments and operations in China

HKEX compliance

• Wuhan YZY Biopharma
• Genertec Universal Medical Group Co., Ltd. 
• PW Medtech Group Limited 
• Rici Healthcare Holdings Limited
• Zhongguancun Science-Tech Leasing 
• PetroChina Company Limited 
• Air China Limited 
• China Pacific Insurance (Group) Co., Ltd. 
• China Telecom 
• CITIC Dameng